NCT04729387 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT04729387
Title	Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected
Recruitment	Active, not recruiting
Gender	both
Phase	Phase III
Variant Requirements	No
Sponsors	Novartis Pharmaceuticals
Indications	peritoneum cancer fallopian tube cancer ovarian endometrial cancer ovarian serous carcinoma
Therapies	Pegylated liposomal doxorubicin Paclitaxel Alpelisib + Olaparib
Age Groups:	senior \| adult
Covered Countries	USA \| TUR \| SVK \| NLD \| ITA \| GBR \| FRA \| FIN \| ESP \| DNK \| DEU \| CZE \| CAN \| BRA \| BEL \| AUT \| AUS \| ARG

NCT04729387
Clinical Trial Detail